Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Linear Ablation Pen Calms Racing Heart

By HospiMedica staff writers
Posted on 01 Apr 2008
A new ablation pen forms long linear cardiac lesions on full-volume beating atria, promoting effective cardiac ablation.

The Coolrail linear ablation pen is designed to facilitate the creation of an expanded cardiac ablation lesion set during a minimally invasive off-pump procedure. More...
The 30 millimeter length electrodes decreases technique and time associated with creating long linear lesions; the distal segment articulates +/-25 degrees to improve access to anatomical structures, and the malleable 7.5 cm distal shaft allows electrodes to be positioned for full contact in various port placements. The ablation pen works in conjunction with the ORLab system, a mapping, recording, and stimulating system which enables electrophysiologists and surgeons to confirm, in the operating room (OR), that the cardiac ablation lines being created are forming conduction block lines across the roof and trigone lesions. The Coolrail linear ablation pen and the ORLab system are products of Atricure (Cincinnati, OH, USA), and have been approved by the U.S. Food and Drug Administration (FDA).

"We are encouraged by the results of the combined use of AtriCure's Coolrail pen and ORLab system to more effectively perform an expanded cardiac ablation procedure,” said Dr. James R. Edgerton, a cardiac surgeon from the Cardiopulmonary Research Science and Technology Institute (CRSTI, Dallas, TX, USA). "Based on our previous research, we anticipate that our investigation of these new products will demonstrate improved results in patients with persistent and long-standing persistent atrial fibrillation.”

"Based on our investigation and collaboration with Dr. Edgerton, I believe that AtriCure's minimally invasive ablation platform has the potential to become the standard of care for chronic atrial fibrillation patients,” said Dr. Warren M. Jackman, M.D., a prominent electrophysiologist and clinical director of the cardiac arrhythmia research institute at the University of Oklahoma Health Sciences Center (OUHSC, Oklahoma City, USA) who developed the protocol used for mapping with the ORLab system.

Cardiac Catheter ablation is performed after an electrophysiology (EP) study, which can identify specific areas of heart tissue where the arrhythmia may start or where abnormal electrical pathways are located inside or outside the atrioventricular (AV) node. In the case of atrioventricular nodal reciprocating tachycardia (AVNRT), for example, ablation has been shown to be eliminated in 96% of cases.


Related Links:
Atricure
Cardiopulmonary Research Science and Technology Institute
University of Oklahoma Health Sciences Center

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Bipolar Coagulation Generator
Aesculap
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.